Osteoporosis International With other metabolic bone diseases Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies

Abstract : Mutations within the gene encoding for the chloride ion channel cystic fibrosis transmembrane conductance regulator (CFTR) results in cystic fibrosis (CF), the most common lethal autosomal recessive genetic disease that causes a number of long-term health problems, as the bone disease. Osteoporosis and increased vertebral fracture risk associated with CF disease are becoming more important as the life expectancy of patients continues to improve. The etiology of low bone density is multifactorial, most probably a combination of inadequate peak bone mass during puberty and increased bone losses in adults. Body mass index, male sex, advanced pulmonary disease, malnutrition and chronic therapies are established additional risk factors for CF-related bone disease (CFBD). Consistently, recent evidence has confirmed that CFTR plays a major role in the osteoprotegerin (OPG) and COX-2 metabolite prostaglandin E2 (PGE2) production, two key regulators in the bone formation and regeneration. Several others mechanisms were also recognized from animal and cell models contributing to malfunctions of osteoblast (cell that form bone) and indirectly of bone-resorpting osteoclasts. Understanding such mechanisms is crucial for the development of therapies in CFBD. Innovative therapeutic approaches using CFTR modulators such as C18 have recently shown in vitro capacity to enhance PGE2 production and normalized the RANKL-to-OPG ratio in human osteoblasts bearing the mutation F508del-CFTR and therefore potential clinical utility in CFBD. This review focuses on the recently identified pathogenic mechanisms leading to CFBD and potential future therapies for treating CFBD.
Type de document :
Article dans une revue
Osteoporosis International, Springer Verlag, 2015, [Epub ahead of print]. 〈10.1007/s00198-015-3343-3〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01221835
Contributeur : Jacky Jacquot <>
Soumis le : mercredi 28 octobre 2015 - 16:23:09
Dernière modification le : mercredi 17 janvier 2018 - 13:14:43
Document(s) archivé(s) le : vendredi 28 avril 2017 - 05:05:10

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Jacky Jacquot, Martial Delion, Sophie Gangloff, Julien Braux, Frédéric Velard. Osteoporosis International With other metabolic bone diseases Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporosis International, Springer Verlag, 2015, [Epub ahead of print]. 〈10.1007/s00198-015-3343-3〉. 〈inserm-01221835〉

Partager

Métriques

Consultations de la notice

141